Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1-Infected Patients Treated with Darunavir
Drugs R D
.
2018 Sep;18(3):249-250.
doi: 10.1007/s40268-018-0243-y.
Authors
Magda Opsomer
1
,
Dessislava Dimitrova
2
,
Johan Verspeelt
3
,
Amy Purrington
4
,
Abdul Mehbob
5
,
Scott Chavers
2
,
Helen Pai
6
,
Simon Vanveggel
3
,
Donghan Luo
2
,
Kimberley Brown
7
,
Christiane Moecklinghoff
8
,
Richard E Nettles
7
,
Katia Boven
2
Affiliations
1
Janssen Research and Development, Beerse, Belgium. mopsomer@its.jnj.com.
2
Janssen Research and Development, LLC, Titusville, NJ, USA.
3
Janssen Research and Development, Beerse, Belgium.
4
Janssen Research and Development, LLC, Horsham, PA, USA.
5
Janssen-Cilag Ltd, High Wycombe, UK.
6
Janssen Research and Development, LLC, Raritan, NJ, USA.
7
Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
8
Janssen EMEA, Neuss, Germany.
PMID:
30079430
PMCID:
PMC6131123
DOI:
10.1007/s40268-018-0243-y
Abstract
In the original publication of the article, Table 2 has been published incorrectly.
Publication types
Published Erratum